Sarepta Therapeutics company information, Employees & Contact Information

Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS Label Sarepta Therapeutics

Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results FinancialContent

Sarepta Therapeutics Provides Statement on ELEVIDYS Sarepta Therapeutics

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society Congress Business Wire

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic Year Yahoo Finance

Sarepta Therapeutics Announces Voluntary Pause of ELEVIDYS Shipments in the U.S. Sarepta Therapeutics

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire

Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy Sarepta Therapeutics

Sarepta Therapeutics to Announce Second Quarter 2025 Financial Results Sarepta Therapeutics

Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy Sarepta Therapeutics

Sarepta Therapeutics Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs Sarepta Therapeutics

Sarepta Therapeutics Provides Update on ELEVIDYS Sarepta Therapeutics

Sarepta Therapeutics Announces Advancement of siRNA Collaboration and Sale of Arrowhead Equity Investment Sarepta Therapeutics

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Recent Corporate Developments Sarepta Therapeutics

Sarepta Therapeutics Announces First Quarter 2025 Financial Results and Recent Corporate Developments Sarepta Therapeutics

Sarepta Therapeutics Announces Second Quarter 2025 Financial Results and Recent Corporate Developments Sarepta Therapeutics

Sarepta Therapeutics Announces Results from Part 2 of the EMBARK Study Demonstrating Sustained Benefits and Disease Stabilization in Ambulatory Individuals with Duchenne Muscular Dystrophy Following Treatment with ELEVIDYS Sarepta Therapeutics

Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility Sarepta Therapeutics

Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4 Sarepta Therapeutics

Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs Sarepta Therapeutics

Second Patient Dies Following Treatment With Sarepta’s DMD Gene Therapy Elevidys CGTLive®

Sarepta Therapeutics Announces Refinancing of Approximately $700 Million of 1.25% Convertible Senior Notes due 2027 Yahoo Finance

Sarepta Therapeutics to Announce Second Quarter 2025 Financial Results Business Wire

Sarepta Therapeutics Presents Data at the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysis of EMBARK Part 2 Yahoo Finance

FDA Gives Sarepta Green Light to Restart Shipment of DMD Gene Therapy Elevidys to Patients Who Are Ambulatory CGTLive®

Sarepta Therapeutics to Present at the BofA Securities Health Care Conference Business Wire

New Death of Patient Treated With Sarepta’s Elevidys Being Investigated by FDA, but Company Claims it is Unrelated to the Therapy CGTLive®

Sarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent Corporate Developments Sarepta Therapeutics

Sarepta Therapeutics to Announce First Quarter 2025 Financial Results Business Wire

U.S. FDA Grants Platform Technology Designation to the Viral Vector Used in SRP-9003, Sarepta’s Investigational Gene Therapy for the Treatment of Limb Girdle Muscular Dystrophy Type 2E/R4 Yahoo Finance

AavantiBio Launches with $107 Million Series A Financing from Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management and Sarepta Therapeutics Bain Capital

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results Business Wire

Sarepta Therapeutics to Announce Second Quarter 2025 Financial Results The AI Journal

Sarepta Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference Business Wire

Sarepta Therapeutics to Announce Second Quarter 2025 Financial Results The Globe and Mail

Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy Sarepta Therapeutics

Sarepta Therapeutics Announces That U.S. FDA has Accepted for Filing and Granted Priority Review for the Biologics License Application for SRP-9001, Sarepta’s Gene Therapy for the Treatment of Ambulant Individuals with Duchenne Muscular Dystrophy Sarepta Therapeutics

Sarepta Therapeutics Announces Intent to Submit an Accelerated Approval Biologics License Application for its Gene Therapy SRP-9001 to Treat Duchenne Muscular Dystrophy Sarepta Therapeutics

Sarepta Therapeutics Submits Biologics License Application for SRP-9001 for the Treatment of Ambulant Patients with Duchenne Muscular Dystrophy Sarepta Therapeutics

Sarepta Therapeutics Acknowledges CHMP Negative Opinion for ELEVIDYS in the European Union Lelezard

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Developments Sarepta Therapeutics

Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors Sarepta Therapeutics

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments Sarepta Therapeutics

Sarepta Therapeutics Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Functional Improvements 18-months After Administration Sarepta Therapeutics

Sarepta Therapeutics’ Gene Therapy SRP-9001 Shows Statistically Significant Functional Improvements Compared to Pre-specified Matched External Control in Part 2 of Study SRP-9001-102 for the Treatment of Duchenne Muscular Dystrophy Sarepta Therapeutics

Sarepta Therapeutics’ Investigational Gene Therapy SRP-9001 for Duchenne Muscular Dystrophy Demonstrates Significant Functional Improvements Across Multiple Studies Sarepta Therapeutics

Sarepta Therapeutics Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4 Sarepta Therapeutics

Sarepta Therapeutics Announces Sale of Priority Review Voucher for $102 million Sarepta Therapeutics

Sarepta Therapeutics’ SRP-9001 Shows Sustained Functional Improvements in Multiple Studies of Patients with Duchenne Sarepta Therapeutics

Sarepta Therapeutics Announces Update on Regulatory Review of SRP-9001 Sarepta Therapeutics

Sarepta Therapeutics’ Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Expression and Functional Improvements 2 Years After Administration Sarepta Therapeutics

Sarepta Therapeutics’ Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy, SRP-9001, Demonstrates Robust Expression and Consistent Safety Profile Using Sarepta’s Commercial Process Material Sarepta Therapeutics

Sarepta Therapeutics Receives Fast Track Designation for SRP-9001 Micro-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy Sarepta Therapeutics

Sarepta Therapeutics Announces That FDA has Lifted its Clinical Hold on SRP-5051 for the Treatment of Duchenne Muscular Dystrophy Sarepta Therapeutics

Sarepta Therapeutics Announces Partnership with Roche in Territories Outside the United States for its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy, SRP-9001 Sarepta Therapeutics

Sarepta Therapeutics Provides Program Update for SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy Sarepta Therapeutics

Sarepta Therapeutics Announces Pricing of $500 Million Public Offering of Common Stock Sarepta Therapeutics

Sarepta Therapeutics Announces Positive Clinical Results from MOMENTUM, a Phase 2 Clinical Trial of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51 Sarepta Therapeutics

Sarepta Therapeutics Announces Top-line Results for Part 1 of Study 102 Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy Sarepta Therapeutics

Sarepta Therapeutics Announces FDA Approval of VYONDYS 53™ (golodirsen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 53 Sarepta Therapeutics

Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results Business Wire

Sarepta Therapeutics’ Gene Therapy Limb-Girdle Muscular Dystrophy Type 2E Clinical Data has been Accepted for a Late-breaking Oral Presentation at the 2019 MDA Clinical and Scientific Conference Sarepta Therapeutics

Sarepta Therapeutics Announces that at the 23rd International Congress of the World Muscle Society, Jerry Mendell, M.D., Presented Positive Updated Results from the Four Children Dosed in the Gene Therapy Micro-dystrophin Trial to Treat Patients with Duc Sarepta Therapeutics

Sarepta Therapeutics Announces that at its First R&D Day, Jerry Mendell, M.D. Presented Positive Preliminary Results from the First Three Children Dosed in the Phase 1/2a Gene Therapy Micro-dystrophin Trial to Treat Patients with Duchenne Muscular Dystr Sarepta Therapeutics

Sarepta Therapeutics Announces FDA Acceptance of Casimersen (SRP-4045) New Drug Application for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 45 Sarepta Therapeutics

Sarepta Therapeutics Enters into Long-term Strategic Manufacturing Partnership with Paragon Bioservices, Greatly Enhancing its Commercial Capacity for Future Gene Therapies Sarepta Therapeutics

Sarepta Therapeutics Signs Agreement with Hansa Biopharma for Imlifidase Sarepta Therapeutics

Sarepta Therapeutics Announces Positive Expression Results from the Casimersen (SRP-4045) Arm of the ESSENCE Study Sarepta Therapeutics

Sarepta Therapeutics Announces Positive and Robust Expression and Biomarker Data from the First Three-Patient Cohort Dosed in the MYO-101 Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy Sarepta Therapeutics

Sarepta Therapeutics Announces First Patient Dosed in Phase III Clinical Trial of SRP-4045 and SRP-4053 for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping Sarepta Therapeutics

Sarepta Therapeutics Announces Grand Opening of its Research and Manufacturing Center at Andover Sarepta Therapeutics

Sarepta Therapeutics Announces Publication of Long-Term Pulmonary Function of Eteplirsen-Treated Patients Compared to Natural History of Duchenne Muscular Dystrophy in The Journal of Neuromuscular Diseases Sarepta Therapeutics

Sarepta Therapeutics and Jerry R. Mendell, M.D. from Nationwide Children’s Hospital to Provide Update on Duchenne Muscular Dystrophy Gene Therapy Program from the 23rd International Annual Congress of the World Muscle Society Sarepta Therapeutics

Sequencing of Phosphorodiamidate Morpholino Oligomers by Hydrophilic Interaction Chromatography Coupled to Tandem Mass Spectrometry ACS Publications

Sarepta Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference Stock Titan

Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors citybiz

Sarepta Therapeutics Opens Genetic Therapies Center of Excellence in Columbus, Ohio Yahoo Finance

Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy Business Wire

Sarepta Therapeutics to Announce First Quarter 2022 Financial Results and Recent Corporate Developments on May 4, 2022 Yahoo Finance

Sarepta Therapeutics to Present at Upcoming Investor Conferences Yahoo Finance

Sarepta Therapeutics Q3 23 Earnings Conference Call At 4:30 PM ET RTTNews

Sarepta Therapeutics Announces Top-line Results for Part 1 GlobeNewswire

Sarepta Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference FinancialContent

Sarepta Therapeutics Announces Agreement for Acquisition of Manufacturing Facility in Massachusetts Sarepta Therapeutics

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) FinancialContent

Sarepta Therapeutics Appoints Michael Chambers and Kathryn Boor, Ph.D., to Its Board of Directors GlobeNewswire

Sarepta Therapeutics Announces FDA Approval of AMONDYS 45™ GlobeNewswire

Sarepta Therapeutics Announces Partnership with Roche in GlobeNewswire

Sarepta Therapeutics Announces Positive Clinical Results GlobeNewswire

Sarepta Therapeutics Announces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year laopinion.com